The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Study Type
OBSERVATIONAL
Enrollment
200
According to the product label
Azienda Ospedaliera Universitaria Integrata Di Verona
Verona, Verona, Italy
RECRUITINGThe percentage of participants still receiving deucravacitinib treatment
Time frame: Week 24 and 52
Absolute Psoriasis Area and Severity Index (PASI)
Time frame: Baseline and Weeks 16, 24 and 52
Participant age in years
Time frame: Baseline
Participant sex
Time frame: Baseline
Participant height in cm
Time frame: Baseline
Participant body mass index in kg/m2
Time frame: Baseline
Participant previous pathologies
Time frame: Baseline
Participan previous surgical procedures
Time frame: Baseline
Date of psoriasis diagnosis
Time frame: Baseline
Number of participants with physical examination according to body systems
Time frame: Baseline
Participant treatment history
Treatment history to describe participants previous treatment(s) received for psoriasis and participants previous treatment(s) received not related to psoriasis
Time frame: Baseline
First line of the email MUST contain NCT # and Site #
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participant comorbidities
Time frame: Baseline
Quality of life as assessed by the Dermatology Life Quality Index (DLQI) questionnaire
Time frame: Baseline and Weeks 16, 24 and 52
Change in symptoms as assessed by the Itch Numerical Rating Scale (Itch-NRS) score
Time frame: Baseline and Weeks 16, 24 and 52
Body Surface Area (BSA)
Time frame: Baseline and Weeks 16, 24 and 52
Static Physician's Global Assessment (sPGA) score
Time frame: Baseline and Weeks 16, 24 and 52
Scalp Specific Physician Global Assessment (ssPGA) score
Time frame: Baseline and Weeks 16, 24 and 52
Scalp Specific Physician Global Assessment (ssPGA) score 0/1
Time frame: Baseline and Weeks 16, 24 and 52
Absolute Psoriasis Area and Severity Index (PASI) 75 and 90
Time frame: Baseline and Weeks 16, 24 and 52
Concomitant psoriasis therapies received
Time frame: Baseline and Weeks 16, 24 and 52